Suppr超能文献

当前先天性心脏病的介入和外科治疗:重点关注瓣膜疾病和心律失常。

Current Interventional and Surgical Management of Congenital Heart Disease: Specific Focus on Valvular Disease and Cardiac Arrhythmias.

机构信息

From the Department of Cardiovascular Surgery (K.A.H., S.M.S., J.A.D.), Departments of Pediatric and Adolescent Medicine, and Molecular Pharmacology and Experimental Therapeutics (T.J.N., B.C.C.), and Division of Pediatric Cardiology (T.J.N., B.C.C.), Mayo Clinic, Rochester, MN.

出版信息

Circ Res. 2017 Mar 17;120(6):1027-1044. doi: 10.1161/CIRCRESAHA.117.309186.

Abstract

Successful outcome in the care of patients with congenital heart disease depends on a comprehensive multidisciplinary team. Surgery is offered for almost every heart defect, despite complexity. Early mortality for cardiac surgery in the neonatal period is ≈10% and beyond infancy is <5%, with 90% to 95% of patients surviving with a good quality of life into the adult years. Advances in imaging have facilitated accurate diagnosis and planning of interventions and surgical procedures. Similarly, advances in the perioperative medical management of patients, particularly with intensive care, has also contributed to improving outcomes. Arrhythmias and heart failure are the most common late complications for the majority of defects, and reoperation for valvar problems is common. Lifelong surveillance for monitoring of recurrent or residual structural heart defects, as well as periodic assessment of cardiac function and arrhythmia monitoring, is essential for all patients. The field of congenital heart surgery is poised to incorporate new innovations such as bioengineered cells and scaffolds that will iteratively move toward bioengineered patches, conduits, valves, and even whole organs.

摘要

先天性心脏病患者的治疗效果取决于一个全面的多学科团队。几乎每一种心脏缺陷都可以通过手术来治疗,无论其复杂程度如何。新生儿期心脏手术的早期死亡率约为 10%,婴儿期后则<5%,90%至 95%的患者在成年后能够拥有良好的生活质量。影像学的进步促进了准确的诊断和干预及手术计划。同样,患者围手术期医疗管理的进步,特别是重症监护的进步,也有助于改善治疗效果。对于大多数缺陷来说,心律失常和心力衰竭是最常见的晚期并发症,瓣膜问题的再次手术也很常见。所有患者都需要进行终身监测,以监测复发性或残留的结构性心脏缺陷,并定期评估心功能和心律失常监测。先天性心脏病外科领域正准备引入新的创新,如生物工程细胞和支架,这些创新将逐步发展为生物工程补丁、导管、瓣膜,甚至整个器官。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验